Ranitherapeutics natalizumab patent?

Do you mean Ranitherapeutics’ interest in natalizumab (e.g., a biosimilar/copy or licensed product), or are you asking for the patent status around natalizumab itself?

A quick clarification: Ranitherapeutics is developing oncology/biologics, and I’m not aware of a widely published public “Ranitherapeutics natalizumab patent” in the same way as you’d see for, say, Teva/Amgen biosimilar filings. Most natalizumab IP is held by the original developer.

What I can tell you (high level)

• Natalizumab (Tysabri®) is originally marketed by Biogen (and formerly used with Elan’s involvement).
• Patent protection for natalizumab typically involves:
  • Composition / formulation patents
  • Manufacturing and process patents
  • New indications and use patents
• The exact “current” status depends heavily on:
  • Country/region (US vs EP vs UK vs JP)
  • Patent family and expiry/adjustments
  • Whether it’s about “composition” vs “method of treatment”

If you tell me these 2 things, I can narrow it down

1. Which jurisdiction do you care about? (US, EP, UK, etc.)
2. Are you looking for Ranitherapeutics’ own patents (their assignee) or the natalizumab patents generally?

If you want, paste any of the following and I’ll help interpret it:

• a patent number
• a link to a patent record
• the application/publication number
• the assignee name shown (e.g., “Ranitherapeutics…”, “Biogen…”, etc.)